A therapeutic regimen (MOPP) that consisted of a combination of mechlorethamine hydrochloride, 3 to 6 mg/sq m intravenously, days 1 and 8, vincristine sulfate, 0.7 or 1.4 mg/sq m intravenously, days 1 and 8, procarbazine hydrochloride, 50 or 100 mg/sq m orally, every day for ten days, and prednisone, 40 mg/sq m orally, every day for ten days, was given every four weeks for 24 weeks to 164 patients with disseminated Hodgkin's disease. Patients in complete remission then received either no therapy or MOPP therapy every eight weeks. One hundred six patients achieved a complete remission (65%). The remission rate for stages IIIA, IIIB, and IVA ranged between 78% and 82%; for IVB it was 56%. At 95 weeks, 78% of the patients receiving maintenance therapy and only 50% of those not receiving maintenance were still in complete remission.
Luce JK, Frei E, Gehan EA, Coltman CA, Talley R, Monto RW. Chemotherapy of Hodgkin's Disease: Maintenance Therapy vs No Maintenance After Remission Induction With Combination Chemotherapy. Arch Intern Med. 1973;131(3):391–395. doi:10.1001/archinte.1973.00320090081009
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: